Oxybutynin chloride
Phase 3Small molecule
Mylan Pharmaceuticals IncOxybutynin chloride is one of 115 small molecule programs targeting Lower Urinary Tract Symptom. It is currently in Phase 3.
4
Indications
12
Total Trials
1
Active Trials
114
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1399 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Oxybutynin chloride
Mylan Pharmaceuticals IncPhase 3
Trexall
Alnylam PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Viagra
VViatris Specialty LLC
Preclinical
Prednisone/prednisolone
RochePreclinical
Ifex
BBaxter Healthcare Corporation
Preclinical
Therapeutic Hydrocortisone
EEastern Cooperative Oncology Group
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Overactive Bladder3 trials
Lower Urinary Tract Symptom1 trial
An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.
Completed·MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.·Phase 3·NCT00338624·420 enrolled
Oral1 trial
3 more indications
Prostate Cancer1 trial
Hot flashes1 trial
Oxybutynin Chloride in Managing Hot Flashes
Completed·—·Phase 3·NCT02961790·150 enrolled
Unspecified3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oxybutynin chloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company